Kenneth Gordon to Adalimumab
This is a "connection" page, showing publications Kenneth Gordon has written about Adalimumab.
Connection Strength
3.700
-
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther. 2020 01; 37(1):364-380.
Score: 0.691
-
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.
Score: 0.629
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
Score: 0.566
-
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr; 29(4):767-76.
Score: 0.484
-
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020 Dec; 21(6):881-890.
Score: 0.185
-
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018 Aug; 32(8):1297-1304.
Score: 0.157
-
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018 06 01; 154(6):676-683.
Score: 0.156
-
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018 01; 178(1):132-139.
Score: 0.151
-
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb; 66(2):241-51.
Score: 0.097
-
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct; 55(4):598-606.
Score: 0.069
-
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S85-91.
Score: 0.067
-
The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005 Nov; 153(5):945-53.
Score: 0.065
-
Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004; 17(5):427-31.
Score: 0.057
-
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945.
Score: 0.043
-
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019 Dec; 46(12):1141-1152.
Score: 0.043
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072.
Score: 0.041
-
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09; 373(2):136-44.
Score: 0.032
-
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013 Apr; 72(4):517-24.
Score: 0.026
-
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71.
Score: 0.024
-
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep; 63(3):448-56.
Score: 0.022
-
Rethinking eligibility creep. J Am Acad Dermatol. 2008 Jul; 59(1):165-7; author reply 167.
Score: 0.020
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
Score: 0.019
-
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15.
Score: 0.019
-
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007 Nov; 48(2):87-101.
Score: 0.018
-
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50.
Score: 0.018